Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: An alternative treatment for C2 deficiency diseases

BMC Immunology

Volumn 11, Issue , 2010, Pages

  Martini, Paolo G V ^a   Cook, Lynette C ^a   Alderucci, Scott ^a   Norton, Angela W ^a   Lundberg, Dianna M ^a   Fish, Susan M ^a   Langsetmo, Knut ^a   Jönsson, Göran ^b   Lood, Christian ^c   Gullstrand, Birgitta ^c   Zaleski, Kate J ^a   Savioli, Nancy ^a   Lottherand, Jason ^a   Bedard, Charles ^a   Gill, John ^a   Concino, Michael F ^a   Heartlein, Michael W ^a   Truedsson, Lennart ^c   Powell, Jan L ^a   Tzianabos, Arthur O ^a  

^a SHIRE   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C2; RECOMBINANT COMPLEMENT COMPONENT C2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C3;

ARTICLE; CHILD; CLONE; COMPLEMENT ACTIVATION; COMPLEMENT COMPONENT C2 DEFICIENCY; COMPLEMENT DEFICIENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; ADULT; CELL LINE; COMPLEMENT CLASSICAL PATHWAY; DRUG EFFECT; GENETICS; IMMUNE DEFICIENCY; IMMUNOLOGY; METABOLISM; PROTEIN BINDING; RECURRENT DISEASE; STREPTOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; CELL LINE, TRANSFORMED; CHILD; COMPLEMENT C1; COMPLEMENT C2; COMPLEMENT C3; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROTEIN BINDING; RECOMBINANT PROTEINS; RECURRENCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 77955677450     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-11-43     Document Type: Article

References (34)

1. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: Lessons from complement deficiencies. Mol Immunol 2009, 46:2774-83. 10.1016/j.molimm.2009.04.029, 19481265.
2. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991, 4:359-95. 358203, 1889047.
3. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol 2001, 76:227-324.
4. Walport MJ. Complement. First of two parts. N Engl J Med 2001, 344:1058-66. 10.1056/NEJM200104053441406, 11287977.
5. Wallis R, Dodds AW, Mitchell DA, Sim RB, Reid KB, Schwaeble WJ. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway. J Biol Chem 2007, 282:7844-51. 10.1074/jbc.M606326200, 17204478.
6. Tedesco F. Inherited complement deficiencies and bacterial infections. Vaccine 2008, (26 Suppl 8):I3-8. 10.1016/j.vaccine.2008.11.010, 19388157.
7. Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjoholm AG. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. Medicine (Baltimore) 2005, 84:23-34. 10.1097/01.md.0000152371.22747.1e, 15643297.
8. Truedsson L, Alper CA, Awdeh ZL, Johansen P, Sjoholm AG, Sturfelt G. Characterization of type I complement C2 deficiency MHC haplotypes. Strong conservation of the complotype/HLA-B-region and absence of disease association due to linked class II genes. J Immunol 1993, 151:5856-63.
9. Wetsel RA, Kulics J, M-L L, Kiepiela P, Akama H, Johnson CAC, Densen P, Colten HR. Type II human complement C2 deficiency. Allele-specific amino acid substitutions (Ser189 - > Phe; Gly444 - > Arg) cause impaired C2 secretion. J. Biol. Chem 1996, 271:5824-31. 10.1074/jbc.271.10.5824, 8621452.
10. Barilla-LaBarca ML, Atkinson JP. Rheumatic syndromes associated with complement deficiency. Curr Opin Rheumatol 2003, 15:55-60. 10.1097/00002281-200301000-00010, 12496511.
11. Ruddy S, Klemperer MR, Rosen FS, Austen KF, Kumate J. Hereditary deficiency of the second component of complement (C2) in man: correlation of C2 haemolytic activity with immunochemical measurements of C2 protein. Immunology 1970, 18:943-54. 1455728, 4987909.
12. Hudson-Peacock MJ, Joseph SA, Cox J, Munro CS, Simpson NB. Systemic lupus erythematosus complicating complement type 2 deficiency: successful treatment with fresh frozen plasma. Br J Dermatol 1997, 136:388-92. 10.1111/j.1365-2133.1997.tb14951.x, 9115923.
13. Steinsson K, Erlendsson K, Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 1989, 32:906-13.
14. Kerr MA, Porter RR. The purification and properties of the second component of human complement. Biochem J 1978, 171:99-107. 1184138, 417728.
15. Nagasawa S, Stroud RM. Cleavage of C2 by C1s into the antigenically distinct fragments C2a and C2b: demonstration of binding of C2b to C4b. Proc Natl Acad Sci USA 1977, 74:2998-3001. 10.1073/pnas.74.7.2998, 431380, 70787.
16. Bentley DR. Primary structure of human complement component C2. Homology to two unrelated protein families. Biochem J 1986, 239:339-45. 1147286, 2949737.
17. Bork K, Horstkorte R, Weidemann W. Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. J Pharm Sci 2009, 98:3499-508. 10.1002/jps.21684, 19199295.
18. Truedsson L, Sjoholm AG, Laurell AB. Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel. Acta Pathol Microbiol Scand [C] 1981, 89:161-6.
19. Davies KA, Erlendsson K, Beynon HL, Peters AM, Steinsson K, Valdimarsson H, Walport MJ. Splenic uptake of immune complexes in man is complement-dependent. J Immunol 1993, 151:3866-73.
20. Fukuoka Y, Seino J, Okuda T, Tachibana T. Purification of the fourth, second and fifth components of mouse complement. Immunology 1984, 51:493-501. 1454464, 6698577.
21. Schultz DR, Arnold PI. Separation of functionally or highly pure C2 from human plasma with Sepharose and a lectin of Euonymus europeus. Acta Pathol Microbiol Immunol Scand Suppl 1984, 284:59-66.
22. Thielens NM, Villiers MB, Reboul A, Villiers CL, Colomb MG. Human complement subcomponent C2: purification and proteolytic cleavage in fluid phase by C1s, C1r2-C1s2 and C1. FEBS Lett 1982, 141:19-24. 10.1016/0014-5793(82)80006-9, 6282646.
23. Wagner E, Platt JL, Howell DN, Marsh HC, Frank MM. IgG and complement-mediated tissue damage in the absence of C2: evidence of a functionally active C2-bypass pathway in a guinea pig model. J Immunol 1999, 163:3549-58.
24. Erlendsson K, Traustadottir K, Freysdottir J, Steinsson K, Jonsdottir I, Valdimarsson H. Reciprocal changes in complement activity and immune-complex levels during plasma infusion in a C2-deficient SLE patient. Lupus 1993, 2:161-5. 10.1177/096120339300200306, 8369807.
25. Alper CA, Xu J, Cosmopoulos K, Dolinski B, Stein R, Uko G, Larsen CE, Dubey DP, Densen P, Truedsson L, et al. Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency. J Clin Immunol 2003, 23:297-305. 10.1023/A:1024540917593, 12959222.
26. Jonsson G, Oxelius VA, Truedsson L, Braconier JH, Sturfelt G, Sjoholm AG. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infection in hereditary C2 deficiency. J Immunol 2006, 177:722-8.
27. Yuste J, Sen A, Truedsson L, Jonsson G, Tay LS, Hyams C, Baxendale HE, Goldblatt F, Botto M, Brown JS. Impaired opsonization with C3b and phagocytosis of Streptococcus pneumoniae in sera from subjects with defects in the classical complement pathway. Infect Immun 2008, 76:3761-70. 10.1128/IAI.00291-08, 2493217, 18541650.
28. Neufeld EF. Enzyme Replacement Therapy. Lysosomal Disorders of the Brain. 2004, 327-338. S.V Oxford University Press, Platt FMaW.
29. Kreuz W, Martinez-Saguer I, Aygoren-Pursun E, Rusicke E, Heller C, Klingebiel T. C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis. Transfusion 2009, 49:1987-95. 10.1111/j.1537-2995.2009.02230.x, 19497056.
30. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009, 15:69-78. 10.1016/j.molmed.2008.12.001, 19162547.
31. Valdimarsson H. Infusion of plasma-derived mannan-binding lectin (MBL) into MBL-deficient humans. Biochem Soc Trans 2003, 31:768-9. 10.1042/BST0310768, 12887300.
32. Petersen KA, Matthiesen F, Agger T, Kongerslev L, Thiel S, Cornelissen K, Axelsen M. Phase I safety, tolerability, and pharmacokinetic study of recombinant human mannan-binding lectin. J Clin Immunol 2006, 26:465-75. 10.1007/s10875-006-9037-z, 16990992.
33. Tabor E, Epstein JS. NAT screening of blood and plasma donations: evolution of technology and regulatory policy. Transfusion 2002, 42:1230-7. 10.1046/j.1537-2995.2002.00183.x, 12430684.
34. Arlaud GJ, Sim RB, Duplaa AM, Colomb MG. Differential elution of Clq, Clr and Cls from human Cl bound to immune aggregates. Use in the rapid purification of Cl subcomponents. Mol Immunol 1979, 16:445-50. 10.1016/0161-5890(79)90069-5, 40870.